MedImmune, AstraZeneca’s global biologics research and development arm, has entered into an agreement to acquire Definiens, a privately-held company that has developed an imaging and data analysis technology known as Tissue Phenomics™. The new technology significantly improves the identification of biomarkers in tumor tissue.
According to the agreement, MedImmune will acquire 100 percent of Definiens’ shares for an initial consideration of $150 million and make additional predetermined milestone payments. Definiens’ business with third-party customers will continue to operate, according to AstraZeneca.
Acquiring Definiens is expected to bolster MedImmune’s focus on the discovery of novel predictive biomarkers in immuno-oncology.